The Obama Administration has embarked on an aggressive course of action that will accelerate the pace at which the integrity of American medicine–is sullied beyond repair. Continue reading →
The primary promoters–inventors, one might say– of diagnosing children with "bipolar" disorder, who for over a decade, aggressively promoted the biopolar diagnosis and use of antipsychotics in children, were disciplined by Harvard University and its affiliated Massachusetts General Hospital.
The authoritative expert who chaired the DSM-IV revision has become a formidable critic whose publicly expressed views about psychiatry’s diagnostic assessments and prescribed treatments–mostly chemical interventions–validate the criticism expressed by the Alliance for Human Research Protection for more than a dozen years. Continue reading →
Hidden financial conflicts-of-interest are sneaking into published drug research through the back door–meta-analyses. Continue reading →
The excerpts from The New Yorker (below) may be read as a companion piece to the Atlantic article profiling Dr. John Ioannidis. However, the opening example that Lehrer uses to make the point that initial impressive positive research findings often weaken . . . Continue reading →
In 2008, 6,485 trials were conducted off shore with almost no FDA oversight. Seventy-eight percent of all human test subjects were enrolled at foreign sites.
We are no longer "blowin’ in the wind." A growing number of prominent physician-scientists, including several former journal editors, and New York Times columnists, have written sobering critiques about the corrupting impact pharmaceutical industry influence has had on medicine. Continue reading →
How many children in foster care serve as human guinea pigs in commercial drug trials?
"The vote is an enormous blow to Avandia and GlaxoSmithKline. The vast majority of panel members voted either to withdraw the drug or to allow continued sales only if strict controls are added" Continue reading →